Q2 results, USD 24M Zambia plant investment approved
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Akums approved Q2 and H1 FY26 results. Standalone H1 revenue fell to Rs 541.76 crore from Rs 645.62 crore, PAT at Rs 68.33 crore vs Rs 92.24 crore. Consolidated H1 PAT was Rs 107.38 crore vs Rs 127.86 crore. Board approved USD 24 million (about Rs 200 crore) staggered investment in a new Zambia subsidiary for a manufacturing plant serving African markets. Auditors flagged an ongoing income tax search matter and a new Section 158BC notice as emphasis of matter.
Sharp standalone profit drop and pending tax matter are negatives, but Zambia plant signals Africa expansion plans.